FDA Advisory Panel To Consider Which COVID-19 Strain To Target With Next Round Of Booster Shots

Reuters (6/3, Santhosh, Leo) reports an FDA advisory committee “will vote whether to recommend that COVID-19 vaccines for 2024-25 should target the JN.1 variant, the most dominant this year, documents filed on Monday showed.” In separate documents, FDA staff “said vaccine makers developing the new booster shots may need to consider targeting one of the JN.1 subvariants such as KP.2, as further evolution of the virus could take it away from the older strain.” That subvariant “has become the dominant strain in the U.S., estimated to account for about 28.5% of cases over a two-week period ended May 25, according to data from the U.S. Centers for Disease Control and Prevention.”